{"id":"fuzheng-huayu-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Mild digestive discomfort"}]},"_chembl":{"chemblId":"CHEMBL942","moleculeType":"Small molecule","molecularWeight":"361.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The herbal combination works by inhibiting hepatic stellate cell activation, reducing extracellular matrix deposition, and promoting apoptosis of activated fibroblasts. It also enhances immune function and reduces oxidative stress in liver tissue, supporting the body's natural ability to resolve existing fibrosis and restore normal hepatic architecture.","oneSentence":"Fuzheng Huayu Tablets is a traditional Chinese medicine formulation that promotes hepatic fibrosis reversal and liver function recovery through anti-inflammatory and antifibrotic pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:47.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatic fibrosis and cirrhosis"},{"name":"Chronic hepatitis B with fibrosis"},{"name":"Liver fibrosis secondary to chronic liver disease"}]},"trialDetails":[{"nctId":"NCT07017426","phase":"NA","title":"Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study","status":"NOT_YET_RECRUITING","sponsor":"Zhiyun Yang","startDate":"2025-07-01","conditions":"Decompensated Hepatitis B Cirrhosis","enrollment":432},{"nctId":"NCT04279197","phase":"PHASE2","title":"Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2020-04-23","conditions":"Pulmonary Fibrosis Due to COVID-19","enrollment":142},{"nctId":"NCT00854087","phase":"PHASE2","title":"Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis","status":"COMPLETED","sponsor":"Tarek Hassanein","startDate":"2010-08","conditions":"Chronic Hepatitis C Infection","enrollment":118},{"nctId":"NCT04645407","phase":"PHASE4","title":"Effects of Fuzheng Huayu Tablets on COVID-19","status":"COMPLETED","sponsor":"ShuGuang Hospital","startDate":"2020-02-01","conditions":"Novel Coronavirus Pneumonia","enrollment":66},{"nctId":"NCT02945956","phase":"PHASE4","title":"Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":192},{"nctId":"NCT02945982","phase":"PHASE4","title":"Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":184},{"nctId":"NCT02241590","phase":"PHASE4","title":"Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Liver Cirrhosis Due to Hepatitis B Virus","enrollment":700},{"nctId":"NCT02241616","phase":"PHASE4","title":"Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2014-09","conditions":"Hepatitis B Virus Related Cirrhosis","enrollment":350},{"nctId":"NCT00543426","phase":"PHASE4","title":"Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2007-09","conditions":"Posthepatitic Cirrhosis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fuzheng Huayu Tablets","genericName":"Fuzheng Huayu Tablets","companyName":"Shanghai University of Traditional Chinese Medicine","companyId":"shanghai-university-of-traditional-chinese-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fuzheng Huayu Tablets is a traditional Chinese medicine formulation that promotes hepatic fibrosis reversal and liver function recovery through anti-inflammatory and antifibrotic pathways. Used for Hepatic fibrosis and cirrhosis, Chronic hepatitis B with fibrosis, Liver fibrosis secondary to chronic liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}